Retrospective Review of Intermediate Oncotype-DX Recurrence Scores Used to Influence Adjuvant Chemotherapy in a Large Breast Unit
Association of Breast Surgery ePoster Library. OConnor A. 05/13/19; 257138; P094
Mr. Alexander OConnor
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
P094
Topic: Non surgical treatments
Introduction: Patient selection for adjuvant chemotherapy (AC) to maximise benefits and minimise unnecessary risk is paramount. The Oncotype-DX, 21-gene assay recurrence-score (RS), is used in our unit to help stratify risk. Publication of the TAILORx trial provided clarity in the benefits of AC in patients with intermediate RS (11-25). This project reviewed our use of AC in intermediate RS patients prior to TAILORx. Methods:A retrospective review of patients diagnosed with ER-positive, HER2-negative, node-negative primary breast cancer between February 2016 and February 2018 with Oncotype-DX RS between 18-30 (meeting inclusion criteria for TAILORx) was undertaken. The use of AC in this group was analysed with reference to TAILORx study outcomes. Results: 81 patients with an intermediate RS (18-30) were identified, age range 34-77 years. 73% (59 patients) had RS of 18-25 and 27% (22 patients) RS of >25. 82% (18/22) patients with RS indicating a significant benefit from chemotherapy following the TAILORx study (RS >25) received chemotherapy. Of the 59 patients with a RS 18-25, 70% (41 patients) were aged >50 and, of these, 37% (15 patients) received chemotherapy, patients who in light of TAILORx could now consider omitting chemotherapy. 30% (18 patients) were 50 years; 44% (8 patients) received chemotherapy (TAILORx outcome suggests likely benefit).Conclusion: Since TAILORx provided clarity in benefits of AC in intermediate RS, our unit can expect to avoid chemotherapy in around 8 patients per year. Furthermore, we can identify a group of younger patients with intermediate RS where AC can provide benefit.
Topic: Non surgical treatments
Introduction: Patient selection for adjuvant chemotherapy (AC) to maximise benefits and minimise unnecessary risk is paramount. The Oncotype-DX, 21-gene assay recurrence-score (RS), is used in our unit to help stratify risk. Publication of the TAILORx trial provided clarity in the benefits of AC in patients with intermediate RS (11-25). This project reviewed our use of AC in intermediate RS patients prior to TAILORx. Methods:A retrospective review of patients diagnosed with ER-positive, HER2-negative, node-negative primary breast cancer between February 2016 and February 2018 with Oncotype-DX RS between 18-30 (meeting inclusion criteria for TAILORx) was undertaken. The use of AC in this group was analysed with reference to TAILORx study outcomes. Results: 81 patients with an intermediate RS (18-30) were identified, age range 34-77 years. 73% (59 patients) had RS of 18-25 and 27% (22 patients) RS of >25. 82% (18/22) patients with RS indicating a significant benefit from chemotherapy following the TAILORx study (RS >25) received chemotherapy. Of the 59 patients with a RS 18-25, 70% (41 patients) were aged >50 and, of these, 37% (15 patients) received chemotherapy, patients who in light of TAILORx could now consider omitting chemotherapy. 30% (18 patients) were 50 years; 44% (8 patients) received chemotherapy (TAILORx outcome suggests likely benefit).Conclusion: Since TAILORx provided clarity in benefits of AC in intermediate RS, our unit can expect to avoid chemotherapy in around 8 patients per year. Furthermore, we can identify a group of younger patients with intermediate RS where AC can provide benefit.
P094
Topic: Non surgical treatments
Introduction: Patient selection for adjuvant chemotherapy (AC) to maximise benefits and minimise unnecessary risk is paramount. The Oncotype-DX, 21-gene assay recurrence-score (RS), is used in our unit to help stratify risk. Publication of the TAILORx trial provided clarity in the benefits of AC in patients with intermediate RS (11-25). This project reviewed our use of AC in intermediate RS patients prior to TAILORx. Methods:A retrospective review of patients diagnosed with ER-positive, HER2-negative, node-negative primary breast cancer between February 2016 and February 2018 with Oncotype-DX RS between 18-30 (meeting inclusion criteria for TAILORx) was undertaken. The use of AC in this group was analysed with reference to TAILORx study outcomes. Results: 81 patients with an intermediate RS (18-30) were identified, age range 34-77 years. 73% (59 patients) had RS of 18-25 and 27% (22 patients) RS of >25. 82% (18/22) patients with RS indicating a significant benefit from chemotherapy following the TAILORx study (RS >25) received chemotherapy. Of the 59 patients with a RS 18-25, 70% (41 patients) were aged >50 and, of these, 37% (15 patients) received chemotherapy, patients who in light of TAILORx could now consider omitting chemotherapy. 30% (18 patients) were 50 years; 44% (8 patients) received chemotherapy (TAILORx outcome suggests likely benefit).Conclusion: Since TAILORx provided clarity in benefits of AC in intermediate RS, our unit can expect to avoid chemotherapy in around 8 patients per year. Furthermore, we can identify a group of younger patients with intermediate RS where AC can provide benefit.
Topic: Non surgical treatments
Introduction: Patient selection for adjuvant chemotherapy (AC) to maximise benefits and minimise unnecessary risk is paramount. The Oncotype-DX, 21-gene assay recurrence-score (RS), is used in our unit to help stratify risk. Publication of the TAILORx trial provided clarity in the benefits of AC in patients with intermediate RS (11-25). This project reviewed our use of AC in intermediate RS patients prior to TAILORx. Methods:A retrospective review of patients diagnosed with ER-positive, HER2-negative, node-negative primary breast cancer between February 2016 and February 2018 with Oncotype-DX RS between 18-30 (meeting inclusion criteria for TAILORx) was undertaken. The use of AC in this group was analysed with reference to TAILORx study outcomes. Results: 81 patients with an intermediate RS (18-30) were identified, age range 34-77 years. 73% (59 patients) had RS of 18-25 and 27% (22 patients) RS of >25. 82% (18/22) patients with RS indicating a significant benefit from chemotherapy following the TAILORx study (RS >25) received chemotherapy. Of the 59 patients with a RS 18-25, 70% (41 patients) were aged >50 and, of these, 37% (15 patients) received chemotherapy, patients who in light of TAILORx could now consider omitting chemotherapy. 30% (18 patients) were 50 years; 44% (8 patients) received chemotherapy (TAILORx outcome suggests likely benefit).Conclusion: Since TAILORx provided clarity in benefits of AC in intermediate RS, our unit can expect to avoid chemotherapy in around 8 patients per year. Furthermore, we can identify a group of younger patients with intermediate RS where AC can provide benefit.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}